These compounds disrupt endocrine function through direct receptor binding and metabolic pathway interference
Women under 40 Premenopausal women on GLP-1 medications face hair loss primarily from telogen effluvium and nutritional depletion
This has been low hanging fruit for FDA for years and it finally appears to be a prominent focus of enforcement efforts This is an important signal
What the clinical trials actually found Six randomized, double-blind, placebo-controlled trials involving over 900 participants have evaluated AOD 9604 in humans
Callaghan BC, Gao L, Li Y, Zhou X, Reynolds E, Banerjee M, et al
The short answer is that general subcutaneous injection education usually points to the abdomen, outer thigh, and upper arm, but that does not make injectable GHK-Cu an approved medication or a safe self-treatment